Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) is a treatment that involves delivering radiation directly to a tumor in the liver. Tiny glass beads containing a radioactive substance called Yttrium-90 are injected into the blood vessels that supply the tumor. This allows for high doses of radiation to be delivered directly to the cancer cells while minimizing exposure to the surrounding healthy tissue.

Capecitabine is a type of chemotherapy medication that is taken orally in the form of a pill. It works by interfering with the growth of cancer cells, slowing down or stopping their ability to multiply. In this trial, Capecitabine is used in combination with Selective Internal Radiation Therapy to enhance the treatment’s effectiveness against cholangiocarcinoma, a type of liver cancer.

Biliary Tract Cancer – This is a type of cancer that occurs in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. It can develop in any part of the bile duct system and is often categorized based on its location, such as intrahepatic, perihilar, or distal. The disease typically progresses slowly, and symptoms may not appear until the cancer is advanced. Common symptoms include jaundice, abdominal pain, and weight loss. As the cancer grows, it can block the bile ducts, leading to further complications. The progression of the disease can vary, with some cases remaining localized while others may spread to nearby organs or lymph nodes.